

Index

abdominal compartment syndrome, 68–9
abdominal insufflation
AVSD, 29–30
Fontan procedure patients, 225
HLHS, stage I palliation, 195
pulmonary hypertension and, 328–9
TAPVR, 175–6
VSD, 12–13
abdominal wall defects, pentalogy of Cantrell, 64–5, 66, 67, 68–9
ABO-incompatible heart transplantation, 292–3
absent pulmonary valve syndrome (APVS).
See also tetralogy of Fallot with absent pulmonary valve syndrome
respiratory pathology, 41, 52, 53–4, 55, 56
TOF with, 41, 52, 53
tracheobronchomalacia, 41, 53–4, 55–6
ventilation strategies, 53–4, 55–6
ACEi. *See* angiotensin converting enzyme inhibitors
acetylcholinesterase inhibitors, post-heart transplantation, 295
ACHD. *See* adult congenital heart disease
acute vasoreactivity testing (AVT), 307
adult congenital heart disease (ACHD)
anesthetic implications, 150–1, 152–3
atrial switch procedures in patients with, 146, 149–50, 156
echocardiography evaluation, 153–6
follow-up, 149–50
afterload, monitoring and management, 133–4
AI. *See* aortic insufficiency
air embolism, craniostostosis repair, 126
airway management
BDG shunt patients, 205
DCM, 249, 250
Duchenne muscular dystrophy patients, 244
lung transplantation, 287
Marfan syndrome, 389
mucopolysaccharidoses, 369–70, 371, 372–3
post-heart transplantation, 302
pulmonary hypertension, 312, 325, 328
TAPVR, 176
VACTERL association, 362–3, 364
vascular rings, 342–3
airway obstruction
APVS and, 52, 53–4, 55, 56

TOF/PA/MAPCAs and, 60–1
Alagille syndrome, 34–5, 61
alcohol ablation, HCM, 116
amiodarone, long QT syndrome, 379
anatomic diagnosis, cardiac catheterization, 4
anatomic shunting, 2, 3
Anderson–Tawil syndrome, 376. *See also* long QT syndrome
anemia, premature infants, 11–12
anesthetic risk. *See also* specific lesions
cardiac catheterization, 87
patient populations with high, 6–7, 79, 107, 111
aneurysms, coarctation of the aorta, 124
angina, HCM, 114
angiography, 5
angiotensin converting enzyme inhibitors (ACEI), 48
Fontan procedure patients, 211, 222, 231
angiotensin receptor blockers (ARBs), Marfan syndrome, 387, 388, 391
antibiotic prophylaxis. *See also* bacterial endocarditis prophylaxis
heterotaxy syndrome, 173
VAD considerations, 274
anticholinergic therapy
DORV patients, 18
post-heart transplantation, 295
anticoagulation therapy
ECMO management, 266
Fontan procedure patients, 211, 216, 222, 231
mBT shunt patients, 18, 19
pulmonary hypertension, 307, 334
VAD use, 271–2, 274, 279, 280
antiemetics, long QT syndrome, 379
antiplatelet therapy
Fontan procedure patients, 211, 222, 231
mBT shunt patients, 18
aorta. *See also* coarctation of the aorta
TOF with overriding, 39–40
aortic arch. *See also* vascular rings
double, 338, 339–40
embryogenesis, 339
right-sided, 339, 340
TOF with, 41
VACTERL association, 360, 362
aortic insufficiency (AI)
after Ross procedure, 94–5
subvalvular aortic stenosis, 98–9

aortic root dilatation, Marfan syndrome, 386–7, 388
aortic stenosis (AS), 83, 90
anatomy, 90, 97–9
anesthetic implications
anesthetic risk, 87, 107, 109, 111
cardiac catheterization special considerations, 87–8
ECG, 87, 100, 106, 108
fasting considerations, 102
hemodynamic management, 109
induction technique, 102–3, 110
maintenance technique, 111
management goals, 88, 96, 102
monitoring, 88, 96, 103, 110–11
outpatient considerations, 111
perioperative preparation and management, 88, 96, 109
postoperative care, 89, 96, 103–4, 111
premedication, 102, 110
preoperative assessment, 86, 95, 101, 102, 108
procedural complications, 89, 94–5
subvalvular, 101–4
supravalvular, 107–11
type of anesthetic, 110
valvular, 94–6
BAV procedure and advantages, 85–6, 92–3
critical, 83, 84, 90–1
echocardiographic findings, 84, 87, 92, 100–1, 102, 108
epidemiology, 97
intervention criteria, 92
Kondo operation, 93, 101
neonatal pathophysiology, 83–4, 90–1
Ross procedure, 93, 94–5
Ross–Kondo procedure, 93–4, 95, 101
SAV procedure and advantages, 85, 86, 93
Shone complex, 129, 130, 131, 133–4
subvalvular, 90, 91, 97
anatomy, 97–9
anesthetic considerations, 101–4
associated lesions, 99
echocardiographic evaluation, 100–1, 102
electrocardiography, 100
interventional cardiac catheterization, 101
medical management, 101
natural history, 100

- subvalvular (cont.)
 physical examination findings, 100
 physiologic considerations, 99–100
 surgical approaches, 101
- supravalvular, 90, 91, 105
 anesthetic considerations, 107–11
 surgical repair indications, 107
 Williams syndrome association, 105–6
 without WS, 106
- treatment options, 84, 92–3
- types, 90, 91
- valvular, 90, 91
 anatomy, 90
 anesthetic considerations, 94–6
 echocardiography, 92
 physiology, 90–2
 surgical approaches, 92–4, 95
- aortic valve. *See also* aortic stenosis
 unicuspid, bicuspid, or quadricuspid, 90, 91, 92
- aortic valvotomy, aortic stenosis, 84, 85, 86, 93
- aortic valvuloplasty. *See* balloon aortic valvuloplasty
- aortopulmonary collaterals. *See also* tetralogy of Fallot with pulmonary atresia and multiple aortopulmonary collaterals
 acquired or persistent, 61
 TOF with, 41, 57, 58, 60
 unifocalization of, 58–60
- apnea, premature infants with, 11–12, 13
- APVS. *See* absent pulmonary valve syndrome
- ARBs. *See* angiotensin receptor blockers
- arrhythmias. *See also specific arrhythmias*
 after atrial switch procedure, 147
- BDG shunt patients, 202
- cardiomyopathy, 256–7
- CCTGA, 160–1
- Duchenne muscular dystrophy, 241
- Ebstein anomaly, 71, 73, 74, 81
- Fontan failure, 229, 231–2, 235
- Fontan procedure patients, 221
- HCM, 115, 120
- long QT syndrome, 374, 379
- Marfan syndrome, 390, 391
- pacemaker or ICD placement
 complications, 245
- post-heart transplantation, 295, 301
- after TOF repair, 46–7, 50–1
- VAD complications, 273
- arrhythmogenic right ventricular dysplasia (ARVD), 246–7, 252–3
- arterial line
 aberrant subclavian artery
 considerations for, 41
- aortic stenosis patients, 103, 110–11
- AVSD patients, 29
- Ebstein anomaly patients, 73
- HCM, 119
- pericardial effusion, 348
- VACTERL association, 364
- arterial switch operation (ASO), 17, 140, 141
 anesthetic implications
 anesthetic risk counselling, 142–3
 induction considerations, 143–4
 monitoring and invasive access
 considerations, 143
 outpatient considerations, 144
 preoperative assessment, 142
 ventilation strategy, 144
- atrial switch procedure versus, 145
- CCTGA, 161–2
 long-term complications, 141
- ARVD. *See* arrhythmogenic right ventricular dysplasia
- AS. *See* aortic stenosis
- ASD. *See* atrial septal defect
- ASO. *See* arterial switch operation
- aspirin, Fontan procedure patients, 211, 222, 231
- asplenia syndrome, 172
- atenolol, Marfan syndrome, 387
- atria, 2
- atrial fibrillation, HCM, 120
- atrial isomerism, 171. *See also* heterotaxy syndrome
 left, 172
 right, 172
- atrial reentrant tachycardia, after TOF repair, 46, 50–1
- atrial septal defect (ASD)
 complete AVSD with, 25, 26
 in parallel circulations, 4
 primum, 20, 21, 22–3, 25, 26
 restrictive, 25–6
 secundum, 20
 TGA with, 138
 TGA with hypoplastic left ventricle, 217, 218
- TOF with, 41
- tricuspid atresia with, 207–8
- atrial septostomy, pulmonary arterial hypertension, 308
- atrial switch procedure, 140
 anesthetic implications
 baffle evaluation, 153–6
 cardiac catheterization procedures, 152–3
 central venous line placement, 152, 153
 high-risk patients, 151–2
 preoperative assessment, 150–1
 procedure location, 156
- arterial switch operation versus, 145
- atrial arrhythmias, 147
- CCTGA, 161–2
- echocardiography, 148, 149, 150–1, 153–6
- follow-up, 149–50
- historical background, 146
- long-term sequelae, 147, 148, 149, 150
 modern day performance of, 146
- Mustard versus Senning procedure, 146, 147, 148
- patient survival and functional status, 149
- RV function, 148–9, 150–1
- atrial tachyarrhythmias, Fontan failure, 229, 231–2, 235
- atrialized ventricle, 71, 75, 76
- atriopulmonary Fontan, 227–8
- atrioventricular concordance, 217
- atrioventricular discordance, 158, 159
- atrioventricular septal defect (AVSD), 20.
See also unbalanced common atrioventricular septal defect
 anatomic defects associated with subtypes, 20, 21
 anesthetic implications
 postoperative care, 24
 specific considerations, 23–4
 unrepaired AVSDs, 23
- associated cardiac anomalies of AV valves and LVOT, 22
- cardiac surgical considerations, 22
- characteristic AVV defect, 22
- clinical implications, 22
- complete, 16, 20–2
 anatomic characteristics, 25, 26
 neonatal symptoms, 27
 physiologic issues, 25
 pulmonary hypertension and, 315–16, 319–20
- echocardiographic and angiographic findings, 23
- partial, 20–2
- physiologic differences between subtypes, 20–2
- Rastelli classification, 26
- residual postoperative defects, 22
- transitional, 20–2
- trisomy 21 and, 22, 27, 28–9
- atrioventricular valves (AVVs). *See also* mitral valve; tricuspid valve
 AVSDs affecting, 20, 22
 common, 25, 26, 27, 28
 regurgitation, AVSDs with, 22–3, 25
- automatic implantable cardioverter defibrillator. *See* implantable cardioverter-defibrillator
- AVSD. *See* atrioventricular septal defect
- AVT. *See* acute vasoreactivity testing
- AVVs. *See* atrioventricular valves
- bacterial endocarditis prophylaxis
 BDG shunt, 202–3
- Ebstein anomaly, 79
- Fontan procedure, 223, 233–4
- guidelines, 167, 168, 202–3, 233–4
- heart transplantation, 295
- Marfan syndrome, 390
- after TOF repair, 49
- truncus arteriosus, 183
- balloon angioplasty, coarctation of the aorta, 123–4

- balloon aortic valvuloplasty (BAV), 84
 anesthetic considerations, 86–9
 procedure, 85–6, 92–3
 results, 89
 SAV versus, 86, 93
- balloon atrial septostomy (BAS)
 DORV, 15–16
 TGA, 138, 139
 TGA with hypoplastic left ventricle, 217, 218
- balloon valvuloplasty
 aortic stenosis, 84
 anesthetic considerations, 86–9
 procedure, 85–6
 SAV versus, 86, 93
- pulmonary stenosis
 anesthetic considerations, 35–8
 complications, 37, 38
 evaluation of, 38
 procedure, 35, 36
 technique, 35, 36, 85–6
- Barth syndrome, 255
- BAS. *See* balloon atrial septostomy
- BAV. *See* balloon aortic valvuloplasty
- BDG shunt. *See* bidirectional Glenn shunt
- Beck's triad, 346
- Berlin Heart EXCOR, 268–9, 270, 277
 anesthetic implications, 271–2, 273–4, 275
 indications, 270–1
 outcomes, 271
- β -blockers
 long QT syndrome, 376
 Marfan syndrome, 387, 388, 391
 post-heart transplantation, 295
- bidirectional Glenn (BDG) shunt
 anesthetic implications
 analgesic options, 205
 cerebral perfusion pressure, 203–4
 discharge criteria, 205–6
 emergence considerations, 205
 endocarditis prophylaxis, 202–3
 hematocrit expectations, 202
 induction method, 204
 intraoperative management goals, 203
 laryngeal mask airway, 205
 monitoring, 203
 premedication, 202
 preoperative assessment and investigations, 201–2
 preoperative fasting considerations, 202
 PVR manipulation, 204
 respiratory tract infection
 management, 201
 ventilation strategy, 204–5
 for Ebstein anomaly, 79
 anesthetic considerations, 79, 80, 81
 fluid management and transfusion strategy, 81
 oxygen saturations after, 80
 pulmonary blood flow and venous return after, 79, 80
 ventilation strategies, 81
- endocarditis prophylaxis, 202–3
 Fontan procedure after, 227
 for HLHS, 191, 198
 blood flow pattern after, 199–201
 hemi-Fontan versus, 199, 200
 oxygen saturation expectations, 201
 physiologic goals, 199
 procedure, 198, 199, 200
 reason for staging, 198–9
 indications, 199
 oxygen saturations, 219
 physiologic goals, 199
 pulmonary vascular resistance, 219
 respiratory infection in patients with, 80
 for TGA with hypoplastic left ventricle, 219
 for tricuspid atresia, 208–9
- Blalock-Taussig shunt (BTS). *See also* modified Blalock-Taussig shunt
 occlusion, 18–19
- blood flow
 effective, 2
 total, 3
- blood loss
 craniosynostosis repair, 125–6, 127
 ECMO bleeding risk, 266
 Fontan procedure patients, 214–15
 transfusion guidelines, 127
 VAD bleeding risk, 274, 280
- bradycardia
 oculocardiac reflex, 18
 trisomy 21 patients, 29
- bronchiolitis obliterans, 283, 284–5
- bronchomalacia. *See* tracheobronchomalacia
- bronchopulmonary dysplasia, 12, 323–4, 325
 anesthetic implications, 326–9
 anesthetic risk, 327
- bronchoscopy, complications, 288
- bronchospasm, BDG shunt, 205
- BTS. *See* Blalock-Taussig shunt
- calcineurin inhibitors, anesthetic agent interactions, 296–7
- calcium channel blockers, and pulmonary hypertension, 307, 320
- cardiac arrest
 heart transplantation failure, 301
 VAD complications, 273
 Williams syndrome, 107
- cardiac catheterization. *See also specific procedures*
 aortic stenosis, 84
 anesthetic considerations, 86–9
 pressure gradient measurement, 92
 procedure, 85–6, 92–3
 results, 89
 SAV versus, 86, 93
 subvalvular, 101
- AVSD, 23
- diagnostic, 3–5
 coarctation of the aorta, 122–3
- normal data, 4, 5
- pulmonary hypertension, 306–7, 308–9, 317, 318, 319, 324–5, 334
- pulmonary stenosis, 33
- TAPVR, 174
- TOF, 42–3
- Williams syndrome, 108
- endotracheal intubation, 302
- interventional, 3–4
 aortic valvuloplasty, 84, 85–9
 after atrial switch procedure, 152–3
 balloon angioplasty, 123–4
 coarctation of the aorta, 123–4
 HCM, 116
 pulmonary valvuloplasty, 35–8
 stent placement, 123–4
- laboratory special considerations, 87–8
- pulmonary stenosis, 33
 anesthetic considerations, 35–8
 complications, 37, 38
 evaluation of, 38
 procedure, 35, 36
 surgical procedures for unsuccessful, 38
- TOF/PA/MAPCAs, 61
- cardiac index (CI), 4, 5
- cardiac magnetic resonance imaging (CMRI), 6
- anesthetic techniques, 356
- Duchenne muscular dystrophy, 241
- Ebstein anomaly, 72–3
- HCM, 115, 116–17
- Kawasaki disease, 354–5
- monitoring, 356–7
- TOF, 49
- Williams syndrome, 108
- cardiac output (CO)
 after BDG shunt, 80
- cardiac catheterization data on, 4, 5
- Fontan procedure patients, 221, 224, 226
- HLHS, 192, 193, 194–5, 196
- pulmonary hypertensive crisis treatment, 310–11
- cardiac pressures
- cardiac catheterization data, 4, 5
- echocardiography data, 6
- cardiac tamponade
 definition and hemodynamic consequences, 345–6
- diagnosis, 346
- echocardiographic findings, 346
- cardiac transplantation. *See* heart transplantation
- cardiomyopathy, 252, 259–60. *See also* dilated cardiomyopathy; hypertrophic cardiomyopathy; restrictive cardiomyopathy
- anesthetic implications
 distraction techniques, 258, 259
- intraoperative goals and plan, 257, 258
- preoperative evaluation, 256–7

- cardiomyopathy (cont.)
 arrhythmogenic right ventricular dysplasia, 246–7, 252–3
 definition, 246
 heart transplantation, 290, 299
 incidence, 253
 left ventricular noncompaction, 246–7, 252–3, 255
 pathophysiology, 258
 subtypes, 246–7, 252–3
- cardiopulmonary resuscitation (CPR),
 Fontan procedure patients, 235
- cardiovascular implantable electronic devices (CIEDs). *See also* implantable cardioverter-defibrillator; pacemaker
 defibrillation or cardioversion considerations, 384
 definition, 377
 dependence, 381
 electromagnetic interference, 164–5, 232, 382
 interrogation, 381–2
 long QT syndrome therapy, 377
 magnet use, 165, 166–7, 383–4
 perioperative management, 164–5, 166–7, 381
 preoperative evaluation, 381, 382
 rate adaptive functions, 383
 reprogramming, 166–7, 382–3
- catheterization. *See* cardiac catheterization
- Catheterization Risk Score for Pediatrics (CRISP), 87
- CAV. *See* coronary allograft vasculopathy
- CAVSD. *See* complete atrioventricular septal defect
- CCTGA. *See* congenitally corrected transposition of the great arteries
- cefazolin, bacterial endocarditis prophylaxis, 183
- central line
 aortic stenosis, 96
 atrial switch procedure patients, 152, 153
 AVSD, 29
 BDG shunt patients, 203
 Fontan procedure patients, 212–13, 223, 233
 pericardial effusion, 348
 VAD considerations, 274
- central venous pressure (CVP), Fontan procedure patients, 209–10, 219, 223
- CentriMag, 268, 278, 279
- cerebral autoregulation, 332, 333
- cerebral perfusion, 333
 anesthetic agent effects, 336
 SCPA effects, 203–4
- CHARGE syndrome, 48
- CHD. *See* congenital heart disease
- chest radiography
 aortic stenosis, 87
 TOF, 42–3
- TOF/APVS, 54
- CHF. *See* congestive heart failure
- chronic allograft dysfunction (CLAD), 284–5
- CI. *See* cardiac index
- CIEDs. *See* cardiovascular implantable electronic devices
- circulation
 parallel, 3, 4
 series, 3, 4
- CLAD. *See* chronic allograft dysfunction
- CMRI. *See* cardiac magnetic resonance imaging
- CO. *See* cardiac output
- coarctation of the aorta, 121
 anatomy and physiology, 121, 122
 anesthetic implications
 hemodynamic goals, 125
 induction and maintenance strategies, 126, 127
 monitoring, 126
 postoperative recovery, 127
 preoperative evaluation, 125
 residual coarctation, 126, 127
 transfusion issues, 127
- associated cardiac defects, 121
- balloon angioplasty, 123–4
- critical, 123
- diagnosis, 122
- echocardiographic and catheterization data, 122–3
- failed repair, 332–3
- hypertension, 122, 124, 125, 127
- recurrence, 124, 125, 332–3
- repair, 123–4
- Shone complex, 121, 129, 130, 131
- surgical approaches, 123–4
- complete atrioventricular septal defect (CAVSD), 16, 20–2
 anatomic characteristics, 25, 26
 neonatal symptoms, 27
 physiologic issues, 25
 pulmonary hypertension and, 315–16, 319–20
- Rastelli classification, 26
- complete heart block
 CCTGA, 160–1
 Fontan failure, 232
- complex shunts, 3
- computed tomography (CT), 6
 Marfan syndrome, 388
 TOF/APVS, 54
 Williams syndrome, 108
- computed tomography angiography (CTA), TOF/PA/MAPCAs, 61–2
- conduction system anomalies. *See also* arrhythmias
 CCTGA, 160–1
 heterotaxy syndrome, 169, 174
- congenital diaphragmatic hernia. *See also* diaphragmatic hernia
- congenital heart disease (CHD). *See also* adult congenital heart disease; specific lesions
 heart failure onset and, 228
 heart transplantation, 290, 299
 NSQIP-P severity classification, 166
 outcomes, 361
 pathophysiologic variability, 2
 physiologic approach, 2–3
 preoperative analysis, 2
 basic concepts and terminology, 2–3, 4
 high-risk patient populations, 6–7, 79, 107
 imaging, 3–6
 pulmonary hypertension and, 314, 315–16
 anesthetic risk, 316, 318–19
 segmental approach, 2
- trisomy 21, 27
- congenital rubella syndrome, 34–5
- congenitally corrected transposition of the great arteries (CCTGA), 137–8, 158
 anatomic characteristics and variations, 158–60
- anesthetic implications
 bacterial endocarditis prophylaxis, 167, 168
 discharge, 167–8
 induction and maintenance methods, 167
 open versus laparoscopic approach, 166
 perioperative considerations, 166–7
 postoperative care, 167
- associated cardiac anomalies, 161
- blood flow, 159, 160
- clinical presentation, 160–1
- conduction system, 160–1
- coronary artery anatomy, 160
- embryologic development, 158–9
- heart failure assessment, 163–4
- long-term sequelae of uncorrected, 162–3
- nomenclature, 159–60
- PA banding indications, 163
- pacemaker/implanted device management
 dependency determination and precautions, 164
 electromagnetic interference, 164–5
 magnet use, 165, 166–7
 perioperative management, 164–5, 166–7
 preoperative evaluation, 164, 165
 reprogramming, 166–7
- surgical interventions, 161–2
 double switch procedure, 161–2, 163
 long-term sequelae, 163
 Mustard procedure, 161–2
 physiologic repair, 162, 163
 physiologic versus anatomic repair, 163
 Senning procedure, 161–2
 Senning-Rastelli procedure, 162, 163

- single ventricle palliation, 162
 congestive heart failure (CHF)
 AVSDs, 22, 25, 27
 CCTGA, 162–4
 DCM, 246, 247
 DORV, 15–16, 17
 signs and symptoms, 10
 VSDs, 10, 12, 13
 coronary allograft vasculopathy (CAV),
 291, 292
 coronary arteries
 anomalies
 DORV, 14–15
 Kawasaki disease, 353
 truncus arteriosus, 180, 181
 Williams syndrome, 105–6, 107, 108,
 111
 CCTGA anatomy, 160
 corticosteroids
 anesthetic agent interactions, 296–7
 stress dose, 296
 CPR. *See* cardiopulmonary resuscitation
 craniosynostosis
 hemodynamic goals, 125
 induction and maintenance anesthetic
 agents and strategies, 126, 127
 inotropic or vasoactive infusions, 127
 intraoperative concerns, 125–6
 monitoring, 126
 pathophysiology, 124
 postoperative recovery, 127
 preoperative evaluation, 125
 preoperative patient communication, 125
 repair, 125–6, 127
 transfusion issues, 127
 CRISP. *See* Catheterization Risk Score for
 Pediatrics
 CT. *See* computed tomography
 CTA. *See* computed tomography
 angiography
 CVP. *See* central venous pressure
 cyanosis. *See also* Tet spells
 aortic stenosis, 90–1
 DORV, 15–16, 17–19
 Ebstein anomaly, 71, 75–6
 Fontan failure, 229
 laparoscopy considerations, 195
 VAD complications, 273
 cyclosporine, 296–7
- DA. *See* ductus arteriosus
 DAA. *See* double aortic arch
 DCM. *See* dilated cardiomyopathy
 dependent (nonrestrictive) shunts, 3
 dexmedetomidine, 63
 BDG shunt patients, 81
 DORV patients, 17–18, 19
 HLHS patients, 194
 long QT syndrome, 378
 pulmonary hypertension effects, 312,
 321
 PVR and cerebral perfusion effects, 336
- after TOF repair, 49
 dextro (D)-transposition of the great
 arteries (d-TGA), 137–8, 145. *See*
 also transposition of the great
 arteries
 hypoplastic left ventricle with, 217–18,
 219–21
 subtypes, 138–9
 dextrocardia, 159–60
 diaphragmatic hernia
 associated anomalies, 262
 classification, 261
 ECMO role in management, 262
 outcomes, 261
 physiologic implications and prognostic
 indicators, 261
 pulmonary hypertension, 261
 surgical repair, 262
 ventilation strategy, 262
 differential cyanosis, aortic stenosis, 90–1
 DiGeorge syndrome, 14–15
 anesthetic implications, 48
 TOF and, 48
 truncus arteriosus with, 181, 182
 dilated cardiomyopathy (DCM), 246,
 252–3
 anesthetic implications
 induction and maintenance
 approaches, 249, 250
 intraoperative hemodynamic
 management, 249, 250
 postoperative disposition, 250
 preoperative evaluation, 248–9
 anesthetic risk, 249, 250
 clinical presentation, 247
 definition, 246
 diagnostic modalities, 248
 Duchenne muscular dystrophy, 240
 hemodynamic considerations, 248, 249,
 250
 incidence, 253
 mechanical circulatory support, 248
 other cardiomyopathy phenotypes
 versus, 246–7
 pathophysiology, 246, 258
 pharmacologic therapies, 248
 physical exam findings, 247
 prognosis, 247, 248
 disordered automaticity, Duchenne
 muscular dystrophy, 241
 diuretic therapy
 perioperative issues, 12, 176, 231
 pulmonary arterial hypertension, 307
 DMD. *See* Duchenne muscular dystrophy
 DORV. *See* double-outlet right ventricle
 double aortic arch (DAA), 338, 339–40
 double discordance, 159, 160, 163. *See also*
 congenitally corrected
 transposition of the great arteries
 double switch procedure, 161–2
 double-outlet right ventricle (DORV), 14
 anatomy, 14, 15, 16
- anesthetic implications
 intraoperative considerations, 18–19
 mBT shunt precautions, 18
 perioperative concerns and risks, 17
 perioperative monitoring, 18
 postoperative recovery concerns, 19
 premedication, 17–18
 preoperative assessment, 17
 specific anesthetic considerations, 18
 sudden oxygenation and
 hemodynamics changes, 19
 associated cardiac defects, 14–15
 clinical presentation, 14, 15–16, 17
 incidence of, 14
 physiologic subtypes, 17
 TGA-type, 15–16, 17
 TOF-type, 15–16, 17
 VSD-type, 15–16, 17
 surgical treatment options, 17
 VSD relationship to great arteries, 14,
 15, 16
- doubly committed ventricular septal
 defect, 15–16
- Down syndrome
 anesthetic concerns, 29
 associated anomalies, 27
 AVSDs with, 22, 27, 28–9
 comorbidities, 319, 320
 DORV with, 14–15
 pulmonary hypertension and, 28–9, 314,
 315–16, 319–20
 TOF with, 41, 47–8
- d-TGA. *See* dextro (D)-transposition of the
 great arteries
- d-transposition of the great arteries. *See*
 dextro (D)-transposition of the
 great arteries
- Duchenne muscular dystrophy (DMD), 239
 anesthetic implications
 complications of pacemaker or ICD
 placement, 245
 ICD insertion considerations, 242–3
 induction and maintenance
 considerations, 243, 244
 intraoperative hemodynamic
 changes, 244
 intraoperative respiratory
 management, 244
 intubation concerns, 244
 malignant hyperthermia risk, 242
 neuromuscular blocking drug use,
 242, 244
 postoperative care, 245
 preoperative discussion, 242
 preoperative evaluation, 241, 242
 vascular access and monitoring, 243
- anesthetic risk, 241, 242–3, 245
 cardiac implications, 240, 241
 DCM, 240
- gastrointestinal implications, 242
 medical therapy, 240
 pathophysiology underlying, 239

- Duchenne muscular dystrophy (cont.)
 perioperative medication
 considerations, 240
 pulmonary function, 240, 241, 242
 symptom presentation and progression,
 239
- ductal stent placement, 366
 ductal-dependent physiology
 aortic stenosis, 83, 84
 HLHS, 187–8
 ductus arteriosus (DA)
 closure of, 33
 PGE₁ reopening of, 35
 dural ectasia, Marfan syndrome, 389
 dynamic obstructions, 3
 RVOTO, 40
 dyspnea, HCM, 114
- Ebstein anomaly (EA), 70, 75
 anatomic and clinical presentations, 70,
 71, 75–6
 anesthetic implications
 anesthetic and surgical risk, 79
 arrhythmia risk, 81
 arterial line monitoring, 73
 BDG shunt physiology, 80
 emergence and postoperative
 concerns, 81
 endocarditis prophylaxis, 79
 fluid management and transfusion
 strategy, 81
 imaging review, 72–3
 induction concerns, 73
 management considerations, 74
 mechanical ventilation concerns, 73–4
 noncardiac surgery after BDG shunt,
 80, 81
 outpatient considerations, 82
 oxygen saturations after BDG shunt,
 80
 post-anesthesia ECG abnormalities,
 74
 postoperative admittance, 74
 premedication, 73
 preoperative evaluation, 72, 79
 recovery location, 81
 respiratory infection considerations,
 80
 ventilation strategy, 73–4, 81
 arrhythmias, 71, 73, 74, 81
 associated defects, 70
 BDG shunt, 79
 cyanosis, 71, 75–6
 inability to wean from PGE₁, 77–8
 long-term strategy, 78–9
 medical management and decision
 making for newborns, 77
 natural course and survival, 76
 prevalence, 71
 pulmonary atresia, 71, 72, 75–6, 77–8
 pulmonary blood flow, 75–6, 77, 81
 after BDG shunt, 79, 80
- PVR, 75–6, 77, 81
 surgical approaches, 77–8
 for inability to wean from PGE₁, 77–8
 indications, 77
 one-and-a-half-ventricle palliation,
 72, 77
 single ventricle palliation, 72, 77, 78–9
 Starnes procedure, 72, 77, 78–9
 two-ventricle repair, 72, 77
 symptomatology, 71
- EC. *See* ectopia cordis
 ECG. *See* electrocardiogram
 echocardiography, 5–6
 aortic stenosis, 84, 87, 92, 100–1, 102, 108
 atrial switch procedure, 148, 149, 150–1,
 153–6
 AVSDs, 23, 29
 cardiac tamponade, 346
 coarctation of the aorta, 122–3
 DCM, 248
 Duchenne muscular dystrophy, 241
 Ebstein anomaly, 72–3
 Fontan procedure patients, 223
 HCM, 115, 116–17
 HLHS, 192
 Kawasaki disease, 354
 Marfan syndrome, 388, 389
 pulmonary hypertension, 306–7, 309,
 316–17, 324
 pulmonic stenosis, 33, 35–6
 TAPVR, 174
 TOF, 42–3, 49
 TOF/PA/MAPCAs, 61–2
 VACTERL association, 362
- ECMO. *See* extracorporeal membrane
 oxygenation
- ectopia cordis (EC), 65, 66, 67
- EF. *See* ejection fraction
- effective blood flow, 2
- Eisenmenger syndrome, 10, 11, 20–2
- ejection fraction (EF), 4, 6
- elastin deficiency, Williams syndrome, 105
- electrical alternans, 346
- electrocardiogram (ECG)
 aortic stenosis, 87, 100, 106, 108
 BDG shunt, 202
 Duchenne muscular dystrophy, 241
 Ebstein anomaly, 71, 74
 heterotaxy syndrome, 174
 Marfan syndrome, 388
 pericardial effusion, 346
 post-heart transplantation, 295
 TOF, 42–3, 49
- electromagnetic interference (EMI),
 164–5, 232, 382
- endocardial cushion defects, 20, 25. *See*
 also atrioventricular septal defect
- endocarditis prophylaxis
 Ebstein anomaly, 79
 after TOF repair, 49
- endothelin receptor antagonists, 307–8, 334
- end-tidal CO₂ (ETCO₂), 88
- epinephrine
 HCM, 119
 intraoperative hypotension, 30
- esmolol, for tet spell management, 43–4
- esophageal atresia
 classifications, 359–60
 diagnosis, 362
 incidence, 359–60
 surgical repair
 airway and ventilation management,
 362–3, 364
 cardiorespiratory compromise, 364
 complications, 365
 ductal stent placement, 366
 extubation, 365
 hypoxemia management, 365–6
 induction and intubation technique,
 363
 monitoring, 364
 open TEF repair, 364–5
 outcomes, 361
 postoperative care, 365
 preoperative bronchoscopy, 363
 preoperative workup, 362
 thoracoscopic, 364
- esophageal foreign bodies, 73
- ETCO₂. *See* end-tidal CO₂
- extracorporeal membrane oxygenation
 (ECMO), 261
- anesthetic implications
 coagulopathy, bleeding, and
 anticoagulation management, 266
 complications, 266
 intensive care unit surgery, 267
 intraoperative hemodynamic
 instability, 266–7
 intraoperative monitoring, 265, 267
 management plan, 265
 personnel, 267
 preoperative assessment, 265
 anticoagulation management, 266
- circuit components, 263, 264
- definition, 262
- diaphragmatic hernia management, 262
- heart transplantation failure, 301
- HLHS, 192, 196, 197
- monitoring, 265, 267
- VAD versus, 264, 276
- veno-arterial, 263, 264, 266–7
- veno-venous, 263, 264, 266–7, 281–2
- ventilator management, 264–5
- fibromuscular ridge, subvalvular aortic
 stenosis, 97–8
- fixed obstructions, 3
- RVOTO, 40
- fluid management
 Ebstein anomaly, 81
 Fontan failure, 234
 lung transplantation, 288
 pulmonary hypertension, 313
 pulmonary stenosis considerations for, 37

- repaired TOF considerations for, 50
TAPVR, 175
Fontan procedure, 207, 217
anesthetic implications
 bacterial endocarditis prophylaxis, 223, 233–4
 blood loss and transfusion, 214–15
 discharge disposition, 236
 emergent surgery considerations, 235–6
 extubation, 216
 fasting instructions, 221–2
 hemodynamic goals, 234
 hypoxemia management, 214
 induction method, 211, 224, 232–3
 intraoperative fluid management, 212
 intraoperative hypotension
 management, 234, 235
 intraoperative temperature
 management, 213
 laparoscopic surgery considerations, 225
long-term prognosis, 225
maintenance considerations, 224, 232–3
management general principles, 213
management goals, 224
monitoring, 212–13, 223, 233
neurologic compromise, 215
outpatient considerations, 223, 236
pacemaker and ICD management, 232
perioperative analgesia, 215–16
perioperative medication
 management, 211, 222, 231
postoperative care, 236
postoperative complications, 216
postoperative disposition, 225
premedication, 211
preoperative assessment, 210–11, 222, 223, 230, 231–2
prone positioning, 213–14
pulmonary artery pressures
 management, 225
regional anesthesia feasibility, 224–5
ventilatory management, 212, 224, 234
atriopulmonary, 227–8
candidates for, 227
circulation determinants, 209–10
circulation physiology, 209–10, 219, 223, 226
for Ebstein anomaly, 77, 78–9
extracardiac, 199, 209, 219–20, 227, 228
failure, 226, 236
 anesthetic options, 232
 atrial tachyarrhythmias, 229, 231–2, 235
 clinical status assessment, 230, 231
 diagnosis, 232
 heart transplantation, 236
 hemodynamic management, 234, 235, 236
onset, 228
- protein-losing enteropathy, 221, 229
symptoms and clinical
 manifestations, 228–30
fenestration, 220–1, 227, 230
for HLHS, 191, 198–9
lateral tunnel, 199, 209, 219–20, 227, 228
long-term complications, 221
oxygen saturations, 220–1, 229, 230
pulmonary vascular resistance, 221
scoliosis surgery and, 210
survival, 209–10
for TGA with hypoplastic left ventricle, 217–18, 219–21
total cavopulmonary anastomosis, 219, 227–8
for tricuspid atresia, 209
foreign bodies, esophageal, 73
furosemide, perioperative issues for
 patients on, 12
- glycosaminoglycans, 367
graft dysfunction. *See primary graft dysfunction*
great arteries, 2
 VSD relationships to, 14, 15, 16
- Haller index, 387–8
HCM. *See hypertrophic cardiomyopathy*
heart failure (HF). *See also congestive heart failure*
 CCTGA, 162–4
 Fontan procedure, onset, 228
 ketamine effects, 249, 250
 mechanical circulatory support for, 270–1, 276
 post-heart transplantation, 294
 truncus arteriosus, 180, 181
heart transplantation, 290
ABO compatibility, 292–3
anesthetic implications
 airway management, 302
 anesthetic risk counselling, 295
 bacterial endocarditis prophylaxis, 295
 cardiac dysrhythmias, 295, 301
 cardiac medication effectiveness, 295
 ECG findings, 295
 fasting considerations, 295
 immunosuppression considerations, 295–7
 induction and maintenance methods, 297, 301–2
 intraoperative complications, 302–3
 monitoring, 297, 301
 postoperative concerns, 298
 postoperative recovery, 303
 preoperative evaluation, 294, 300–1
 preoperative preparation, 301
 same-day surgery considerations, 297–8
 special drug and equipment considerations, 297
 stress dose steroids, 296
- anesthetic risk, 295, 301
complications, 291, 292, 299–300
epidemiology, 299
for Fontan failure, 236
heart failure, 294, 299
 anesthetic management, 300–3
 anesthetic risks, 301
 ECMO, 301
immunosuppression, 295–6
 anesthetic agent interactions, 296–7
- indications, 290, 299
outcomes, 291, 299
physiology, 293
surgical techniques, 290–1, 292, 293
- HeartMate 3, 268
HeartMate II, 268, 277
HeartWare, 268, 277, 278
hematocrit
 BDG shunt patients, 202
Fontan procedure patients, 214
TOF, 42–3
- hemi-atrial switch procedure, 146
hemi-Fontan procedure
 Fontan procedure after, 227
 for HLHS, 191, 198, 199, 200
 for tricuspid atresia, 208–9
- hepatorenal dysfunction, Fontan failure, 229
heterotaxy syndrome, 146, 169
anesthetic implications
 induction and maintenance methods, 174–5
 intraoperative concerns, 175–6
 malrotation management, 173
 monitoring, 174
 postoperative management, 176
 preoperative evaluation, 174
 risk discussion, 173–4
 ventilation strategy, 175
conduction anomalies, 169, 174
postoperative sequelae, 171
TAPVR with, 169–70, 171
 classification, 172
 infection-related precautions, 173
 organ involvement, 172
 perioperative outcomes, 171
 visceral situs in, 2
- HF. *See heart failure*
- HLHS. *See hypoplastic left heart syndrome*
- HOCM. *See hypertrophic obstructive cardiomyopathy*
- Hurler syndrome, 254, 367
anesthetic implications
 aerodigestive evaluation
 considerations, 372
 airway management, 369–70, 371, 372–3
extubation and postoperative
 management, 373
induction and maintenance methods, 372
- intraoperative neuromonitoring, 371–2
laryngospasm management, 373

- Hurler syndrome (cont.)
 mitral regurgitation, 371
 preoperative assessment, 369
 procedure location, 372
 associated cardiac defects, 369
 characteristic features, 368
 classification, 367, 368
 glycosaminoglycans, 367
 pathogenesis, 367–8
 treatment, 369
 variants, 368
- hybrid stage I palliation, 190, 191. *See also* stage I palliation
- hypercyanotic spells. *See* tet spells
- hypertension
 coarctation of the aorta, 122, 124, 125, 127
 HCM, 120
 hypoxemia with, 195
 Marfan syndrome, 389, 391
- hypertrophic cardiomyopathy (HCM), 113, 114, 246–7, 252–3, 258
 anatomic manifestations, 253–4
 anesthetic implications
 atrial fibrillation management, 120
 emergence, 118
 hypertension management, 120
 induction technique, 117–18, 119
 maintenance technique, 118
 management goals, 117, 119, 257
 monitoring, 117, 119
 perioperative management, 117, 118, 119
 post-induction hypotension, 119
 postoperative care, 118
 postoperative hemorrhage
 management, 118, 119, 120
 potential complications, 116
 preoperative evaluation, 116–17
 procedure venue, 117
 ventilation strategy, 120
 anesthetic management, 117–18
 characteristics, 113
 clinical presentation, 254
 diagnostic imaging, 115
 genetics, 113, 114
 incidence, 253
 medical therapy, 116, 254
 myocardium effects, 114
 obstructive cardiomyopathy, 115–16
 primary, 253
 secondary, 253
 surgical approaches, 116, 254
 symptoms, 114, 115
- hypertrophic obstructive cardiomyopathy (HOCM), hypertrophic cardiomyopathy versus, 115–16
- hypoalbuminemia, Fontan failure, 229
- hypoplastic left heart syndrome (HLHS), 187, 198. *See also* stage I palliation; stage II palliation
 anatomy, 187, 198
 anesthetic risk, 192, 193
- blood flow, 187–8
 stage I palliation, 190
 stage II palliation, 199–201
- hemodynamic goals, 191, 192, 193–4
 incidence, 187
 $Q_p:Q_s$ ratio, 191, 192, 193–5
 surgical approaches
 Fontan procedure, 191, 198, 199
 hybrid procedure, 190, 191
 reason for staging, 198–9
 stage I (Norwood) palliation, 188, 189–90, 191, 192, 198
 stage II palliation, 191, 198, 199–201
- hypotension
 AVSD patients, 30, 31
 cardiomyopathy, 115–16, 119, 247, 250, 257
 coarctation of the aorta, 125
 Fontan failure, 234, 235
 heart transplantation failure, 302–3
 HLHS patients, 192, 193–4
 intraoperative, AVSD patients, 30, 31
- ICD. *See* implantable cardioverter-defibrillator
- idiopathic pulmonary arterial hypertension (IPAH), 306
 anesthetic management goals, 309
 preoperative considerations, 309
- immunosuppression therapy
 heart transplantation, 295–7
 lung transplantation, 285–6, 287
- implantable cardioverter-defibrillator (ICD)
 after atrial switch procedure, 147, 148
 complications, 245
 defibrillation or cardioversion
 considerations, 384
 defibrillator code, 381
 dependency determination and
 precautions, 164
 Duchenne muscular dystrophy, 242–3, 245
 electromagnetic interference, 164–5, 232, 382
 Fontan failure, 232
 HCM, 116, 117, 118, 119
 indications, 46–7, 380
 long QT syndrome therapy, 377
 magnet use, 165, 166–7, 383–4
 monitoring, 383
 perioperative management, 117, 118, 119, 164–5, 166–7, 232, 381
 preoperative evaluation, 164, 165, 381, 382
- rate adaptive functions, 383
 reprogramming, 166–7, 382–3
- infective endocarditis. *See* bacterial endocarditis prophylaxis
- inhaled nitric oxide (iNO)
 BDG shunt patients, 204
- pulmonary hypertension, 11, 320, 321, 325
 pulmonary hypertensive crisis, 310
 VSD patients, 11
- inlet ventricular septal defect, 9, 10, 25, 26
- iNO. *See* inhaled nitric oxide
- insufflation. *See* abdominal insufflation
- intact ventricular septum, TGA with, 138, 139, 141
- intraabdominal pressure, omphalocele repair, 67, 68–9
- intraatrial baffles
 complications, 147, 148, 152
 echocardiography evaluation, 153–6
- intravenous agents, pulmonary hypertension effects, 312
- IPAH. *See* idiopathic pulmonary arterial hypertension
- Jervell syndrome, 376. *See also* long QT syndrome
- Kawasaki disease, 352
 anesthetic implications
 CMRI considerations, 356
 induction and maintenance methods, 357
 management plan, 355
 monitoring, 356–7
 perioperative medication
 management, 355–6
 premedication, 356
 preprocedural assessment, 355
 preprocedural preparation, 357
 anesthetic risk, 357–8
 CMRI, 354–5
 definition, 352
 diagnosis, 352, 353
 echocardiography, 354
 epidemiology, 352
 pathophysiology, 352, 353
 phases, 353
 prognosis, 354
 relevance, 353
 selection of imaging technique, 354
 sequelae, 353
 treatment recommendations, 353–4
- ketamine
 Duchenne muscular dystrophy patients, 243, 244
 heart failure patients, 249, 250
 pulmonary hypertension effects, 312, 321
 PVR and cerebral perfusion effects, 336
 TOF patients, 43
 Williams syndrome patients, 110
- Konno operation, 93, 101
- Lange–Nielsen syndrome, 376. *See also* long QT syndrome
- laparoscopic surgery
 AVSD considerations, 29–30
 Fontan procedure patients, 225

- HLHS, stage I palliation, 195–6
open approach versus, 166
pulmonary hypertension, 328–9
TAPVR, 175–6
VSD considerations, 12–13
laryngospasm, 205, 373
LCSD. *See left cardiac sympathetic denervation*
left atrial isomerism, 172
left cardiac sympathetic denervation (LCSD), 377
left dominance, unbalanced AVSD, 28
left ventricle (LV). *See also hypoplastic left heart syndrome*
 Ebstein anomaly, 76
 hypoplastic, TGA with, 217–18, 219–21
 pulmonary hypertension effects, 325
left ventricular assist device (LVAD), 268–9, 270, 271. *See also Berlin Heart EXCOR*
 right ventricular failure, 278, 279
 right ventricular function, 277
left ventricular (LV) diverticulum, pentalogy of Cantrell, 65, 66
left ventricular (LV) hypertrophy, aortic stenosis, 83–4, 91–2, 99–100
left ventricular noncompaction cardiomyopathy (NCM), 252–3
 definition, 255
 other cardiomyopathy phenotypes versus, 246–7
left ventricular outflow tract (LVOT)
 AVSDs affecting, 20, 22, 23
 cardiomyopathy effects, 256–7
left ventricular outflow tract obstruction (LVOTO)
 aortic stenosis, 85, 86
 subvalvular, 97–8, 99–100, 101, 102
 valvular, 90, 91, 93
 AVSD, 22, 23
 CCTGA, 161
 HCM, 113, 114, 115–16, 117, 118, 119, 120, 253–4
 Shone complex, 129, 130, 131
 TGA, 138, 139, 140–1
left-sided obstructive lesions, anesthetic risk, 6–7
left-to-right (L-to-R) shunting
 AVSDs, 25–6
 VSDs, 9, 10, 12–13
levo (L)-transposition of the great arteries (L-TGA), 137–8, 146, 158–9. *See also congenitally corrected transposition of the great arteries*
long QT syndrome (LQTS), 374
 acquired, 376
 anesthetic implications
 antiemetics, 379
 induction and maintenance agents, 378
 medication interactions, 377–8
 monitoring, 378
nondepolarizing muscle relaxants, 378–9
pain management, 379
postoperative considerations, 379
premedication, 378
preoperative evaluation, 377
torsades de pointes management, 379
CIED therapy, 377
clinical presentation, 374, 375
congenital, 374, 375–6
 Anderson–Tawil syndrome, 376
 Jervell syndrome, 376
 Lange–Nielson syndrome, 376
 Timothy syndrome, 376
 definition, 374
 genetics, 375–6
 medical management, 376
 mortality, 376
 pacemaker therapy, 377
 types
 long QT1, 375, 376
 long QT2, 375, 376
 long QT3, 375, 376
1-TGA. *See levo (L)-transposition of the great arteries*
L-to-R shunting. *See left-to-right shunting*
lung development, TOF/PA/MAPCAs, 58
lung transplantation, 283
anesthetic implications
 airway management, 287
 bronchoscopic procedure complications, 288
 extubation, 288
 fluid balance, 288
 induction and maintenance methods, 287, 288
 monitoring, 287
 outpatient considerations, 288
 premedication, 287, 288
 preoperative evaluation, 286, 287
 ventilation strategy, 288
complications, 284
 bronchiolitis obliterans, 283, 284–5
 chronic allograft dysfunction, 284–5
 primary graft dysfunction, 284–5
 rejection, 284
 restrictive allograft syndrome, 284–5
immunosuppression, 285–6, 287
indications, 283
medical comorbidities, 285–6
physiologic changes, 285
survival, 283, 284
LV. *See left ventricle*
LVAD. *See left ventricular assist device*
LVOT. *See left ventricular outflow tract*
LVOTO. *See left ventricular outflow tract obstruction*
magnetic resonance imaging (MRI). *See also cardiac magnetic resonance imaging*
 anesthetic issues, 335, 336
Marfan syndrome, 388
TOF/APVS, 54
malignant hyperthermia, 242
MAPCAs. *See multiple aortopulmonary collaterals*
Marfan syndrome (MFS), 386
 airway issues, 389
 anesthetic implications
 airway concerns, 389
 arrhythmia onset, 390, 391
 bacterial endocarditis prophylaxis, 390
 emergence and extubation, 391
 hemodynamic goals, 389
 history of mitral valve repair, 390
 induction methods, 390
 maintenance concerns, 390
 monitoring, 389
 patient positioning, 390
 perioperative medication continuation, 388
 postoperative recovery, 391
 premedication, 389
 preoperative diagnostic studies, 388
 preoperative evaluation, 388
 regional or epidural anesthesia concerns, 389
cardiovascular abnormalities, 386–7
definition, 386
medical therapy, 387, 388, 391
pectus excavatum correction, 387–8
z-score, 387
mBTS. *See modified Blalock-Taussig shunt*
mechanical circulatory support (MCS). *See also extracorporeal membrane oxygenation; ventricular assist device*
 indications, 270–1, 276
 types, 276
membranous subvalvular aortic stenosis, 97–8
MFS. *See Marfan syndrome*
midazolam, 49, 73
 pulmonary hypertension effects, 312
milrinone
 Fontan procedure patients, 214–15
 pulmonary hypertensive crisis, 311
 pulmonic stenosis, 35
mitral regurgitation (MR), 371
mitral valve. *See also mitral regurgitation; Shone complex*
 anterior leaflet cleft, 20, 21
 parachute, 129, 130, 131
 systolic anterior motion, 114
mitral valve repair, Marfan syndrome, 390
modified Blalock-Taussig shunt (mBTS)
DORV, 17, 18–19
Ebstein anomaly, 77–8
HLHS, 189, 190, 191, 192, 194, 196, 198–9
monitoring, 218
pulmonary stenosis, 38
TAPVR and heterotaxy syndrome, 173–5

- modified Blalock-Taussig shunt (cont.)
 TGA with hypoplastic left ventricle, 217–18
 thrombosis, 194, 196
 tricuspid atresia, 208–9
- moyamoya disease, 331
 anesthetic management, 334–7
 associated conditions, 331
 cerebral autoregulation, 332, 333
 coarctation of the aorta with, 332–3
 definition, 331
 diagnosis, 331–2
 treatment, 332
- MPS. *See* mucopolysaccharidoses
- MR. *See* mitral regurgitation
- MRI. *See* magnetic resonance imaging
- mucopolysaccharidoses (MPS). *See also* Hurler syndrome
 airway management, 369–70, 371, 372–3
 anesthetic concerns, 367
 classification, 367, 368
 glycosaminoglycans, 367
 preoperative assessment, 369
- multiple aortopulmonary collaterals (MAPCAs). *See also* tetralogy of Fallot with pulmonary atresia and multiple aortopulmonary collaterals
 acquired or persistent, 61
 direct, 58
 indirect, 58
 TOF with, 41, 57, 58, 60
 unifocalization of, 58–60
- muscular ventricular septal defect, 9, 10
- Mustard procedure, 140, 146, 147, 161–2
- myectomy, HCM, 116
- National Surgical Quality Improvement Project-Pediatrics (NSQIP-P), CHD severity classification, 166
- NCM. *See* left ventricular noncompaction cardiomyopathy
- neostigmine, post-heart transplantation, 297
- neuromuscular blocking drugs, Duchenne muscular dystrophy, 242, 244
- nicardipine, 127
- Nikaidoh procedure, 141
- nitric oxide. *See* inhaled nitric oxide
- noncommitted ventricular septal defect, 15–16
- noncompaction cardiomyopathy. *See* left ventricular noncompaction cardiomyopathy
- nonrestrictive shunts. *See* dependent shunts
- nonrestrictive ventricular septal defect, 10, 25–6
- Noonan syndrome, 34–5
- Norwood procedure, 189–90, 198. *See also* stage I palliation
- NSQIP-P. *See* National Surgical Quality Improvement Project-Pediatrics
- Nuss procedure, 387–8
 complications, 390, 391
 CPR during or after, 391
 postoperative pain strategies, 388–9
- obliterative bronchiolitis, 283, 284–5
- obstructions
 dynamic, 3, 40
 fixed, 3, 40
- obstructive airway disease
 APVS and, 52, 53–4, 55, 56
 TOF/PA/MAPCAs and, 60–1
- oculocardiac reflex, 18
- omphalocele
 abdominal compartment syndrome, 68–9
 pentology of Cantrell, 64–5, 66, 67
- one-and-a-half-ventricle palliation, Ebstein anomaly, 72, 77
- opioids
 pulmonary hypertension effects, 312
 PVR and cerebral perfusion effects, 336
- orthotopic heart transplantation. *See* heart transplantation
- overriding aorta, TOF with, 39–40
- PA. *See* pulmonary artery
- pacemaker. *See also* cardiovascular implantable electronic devices; implantable cardioverter-defibrillator
 after atrial switch procedure, 147, 148
 complications, 245
 defibrillation or cardioversion considerations, 384
 dependence, 381
 dependency determination and precautions, 164
 dual chamber, 380
 Duchenne muscular dystrophy, 242–3, 245
 electromagnetic interference, 164–5, 232, 382
 Fontan failure, 229, 232
 indications, 380
 interrogation, 381–2
 long QT syndrome therapy, 377
 magnet use, 165, 166–7, 383–4
 monitoring, 383
 multisite pacing, 380
 pacemaker code, 380
 perioperative management, 164–5, 166–7, 232, 381
 preoperative evaluation, 164, 165, 381, 382
 rate adaptive functions, 383
 rate modulation, 380
 reprogramming, 166–7, 382–3
 single chamber, 380
- PAH. *See* pulmonary arterial hypertension
- palpitations, HCM, 115
- Panama classification, 333
- parachute mitral valve, 129, 130, 131
- parallel circulation, 3, 4, 137–8, 174–5, 188, 217
- partial atrioventricular septal defect, 20–2
- patent ductus arteriosus (PDA)
 aortic stenosis, 83–4, 90–1
 coarctation of the aorta, 122, 123
 Ebstein anomaly, 75–6, 77
 HLHS, 187–8
 parallel circulations, 3, 4
 pulmonic stenosis, 35
 stent placement, 366
 TGA, 137, 138, 139
 TGA with hypoplastic left ventricle, 217–18
 TOF/APVS, 53
 TOF/PA/MAPCAs, 58, 60
 TOF-type DORV, 15–16
 tricuspid atresia, 208
 unbalanced AVSD, 28, 29
- VACTERL association, 360–1, 365–6
- patent foramen ovale (PFO)
 pulmonary hypertension and, 332, 333
 TGA, 137, 138, 139
 TOF, 41
- PBF. *See* pulmonary blood flow
- PCE. *See* pericardial effusion
- PDA. *See* patent ductus arteriosus
- pectus excavatum
 CPR strategy, 391
 Nuss correction, 387–9, 390, 391
- Pediatric Difficult Intubation Registry, airway management, 370, 371
- pentology of Cantrell (POC), 64
- abdominal wall defects, 64–5, 66
- anatomy, 64
- anesthetic implications
 abdominal compartment syndrome, 68–9
 induction and intubation considerations, 68
 intraoperative concerns for omphalocele repair, 67
- intraoperative concerns for sternal malformation repair, 67–8
- postoperative concerns, 69
- preoperative evaluation, 67
- prognosis, 69
- vascular access and monitoring, 68
- ventilatory strategies, 68
- associated anomalies, 64
- cardiac defects, 65, 66
- classification, 64
- ectopia cordis, 65, 66, 67
- LV diverticulum, 65, 66
- prevalence, epidemiology, and embryology, 64
- pulmonary hypertension, 65–6, 68
- sternal malformations, 65, 67
- surgical options and strategies, 66–7
- pentology of Fallot, 41
- pericardial effusion (PCE), 345

- anesthesia implications
 fasting considerations, 347
 hemodynamic goals, 349
 induction method, 348–9
 management plan, 348
 monitoring, 348
 past medical history, 347
 physical examination, 347
 sedation, 349
 separation anxiety, 347–8
 cardiac tamponade and, 345–6
 cardiopulmonary interactions, 347
 definition and causes, 345
 ECG findings, 346
 hemodynamic goals, 349
 hemodynamic monitoring findings, 346
 pericardiocentesis, 349–50
 complications, 350–1
 pericardiocentesis, 349–50
 complications, 350–1
 perimembranous ventricular septal defect, 9
 peripherally inserted central catheter
 (PICC), placement, 311
 PFO. *See* patent foramen ovale
 PGD. *See* primary graft dysfunction
 PGE₁. *See* prostaglandin E₁
 PH. *See* pulmonary hypertension
 phenylephrine
 HCM, 119
 intraoperative cyanosis, DORV patients
 with, 18–19
 tet spell management, 43–4, 361
 VSD patients, 12
 phosphodiesterase inhibitors, 307–8, 320,
 325, 334
 physiologic approach, 2–3
 physiologic shunting, 2, 3
 PI. *See* pulmonary insufficiency
 PICC. *See* peripherally inserted central
 catheter
 Pierre Robin sequence, 182
 pink tet, 42, 360–1
 plastic bronchitis, 221, 229
 PLE. *See* protein-losing enteropathy
 pneumothorax
 Marfan syndrome, 390
 pacemaker or ICD placement
 complications, 245
 POC. *See* pentalogy of Cantrell
 positive pressure ventilation (PPV)
 Fontan procedure patients, 224, 234
 HLHS
 BDG shunt patients, 204–5
 stage I palliation patients, 194
 TAPVR, 175
 TGA, 144
 Potts shunt, 308
 PPV. *See* positive pressure ventilation
 PR. *See* pulmonary regurgitation
 preexcitation, Ebstein anomaly, 71
 premature infants
 anemia, 11–12
 apnea, 11–12, 13
 bronchopulmonary dysplasia, 12,
 323–4, 325
 chronic lung disease, 11–12
 hospital discharge, 13
 pulmonary hypertension, 323
 airway management, 325
 anesthetic implications, 326–9
 anesthetic risk, 327
 bronchopulmonary dysplasia and,
 323–4, 325
 cardiac function changes, 325
 definition, 323
 diagnosis, 324–5
 iNO effects, 325
 medical management, 325
 risk factors, 324
 screening, 324
 shunt effects, 325–6
 sildenafil effects, 325
 VSDs, 9, 10, 11–12, 13
 preoperative analysis, 2
 basic concepts and terminology, 2–3, 4
 high-risk patient populations, 6–7, 79,
 107, 111
 imaging, 3–6
 pressure gradients
 cardiac catheterization data, 4, 5
 echocardiography data, 6
 preterm infants. *See* premature infants
 primary graft dysfunction (PGD), lung
 transplantation, 284–5
 propofol
 BDG shunt patients, 204
 Duchenne muscular dystrophy patients,
 243, 244
 pulmonary hypertension effects, 312, 321
 PVR and cerebral perfusion effects, 336
 Williams syndrome patients, 110
 prostacyclin analogs
 pulmonary arterial hypertension, 307–8,
 334
 pulmonary hypertension, 320, 321
 prostaglandin E₁ (PGE₁)
 adverse effects, 35, 188
 aortic stenosis, 84, 90–1
 AVSD, 28, 29
 coarctation of the aorta, 123
 DORV, 15–16
 Ebstein anomaly, 77
 inability to wean from, 77–8
 HLHS, 187–8
 pulmonic stenosis, 35, 38
 TGA, 138, 139
 TGA with hypoplastic left ventricle,
 217–18
 tricuspid atresia, 208
 VACTERL association, 361, 365–6
 protein-losing enteropathy (PLE), 221, 229
 PS. *See* pulmonary (pulmonic) stenosis
 pulmonary arterial hypertension (PAH), 305
 acute vasoreactivity testing, 307
 anesthetic management goals, 309
 anesthetic risk, 308–9
 classification, 306, 308
 definition, 305
 diagnosis, 306–7
 idiopathic, 306, 309
 pathophysiology, 305–6
 preoperative planning, 309
 treatment
 goals, 307
 initial options, 307
 procedural options, 308
 targeted therapies, 307–8, 309
 in trisomy 21 patients, 28–9
 pulmonary artery (PA)
 banding
 AVSDs, 22
 CCTGA, 163
 hybrid stage I palliation of HLHS, 191
 hypoplasia
 DORV, 14–15
 pentalogy of Cantrell, 65–6
 supravalvular stenosis, 105–6
 truncus arteriosus, 178–9
 pulmonary atresia. *See also* tetralogy of
 Fallot with pulmonary atresia and
 multiple aortopulmonary
 collaterals
 Ebstein anomaly, 71, 72, 75–6, 77–8
 hypoplastic left ventricle with, 217–18
 TOF, 41, 57, 58
 VSD/MAPCAs, 58, 59
 pulmonary blood flow (PBF, Q_p). *See also*
 Q_p:Q_s ratio
 cardiac catheterization data, 4, 5
 Ebstein anomaly, 75–6, 77, 81
 after BDG shunt, 79, 80
 effective, 2
 Fontan procedure patients, 209–10, 219,
 223, 226
 mBT shunt effects, 218
 TOF/PA/MAPCAs, 57, 58, 60
 total, 3
 tricuspid atresia, 208
 pulmonary function studies
 Duchenne muscular dystrophy, 241
 Marfan syndrome, 388
 pulmonary hypertension (PH), 305. *See*
 also pulmonary arterial
 hypertension
 acute vasoreactivity testing, 307
 anesthetic implications
 airway management, 312, 325, 328
 anesthetic medication effects, 312, 321
 emergence precautions, 313
 fluid management, 313
 induction and maintenance methods,
 311–12, 328, 336–7
 laparoscopic approach, 328–9
 management goals, 309, 335–6
 monitoring, 311, 321, 327–8, 337
 MRI issues, 335, 336

- pulmonary hypertension (PH) (cont.)
 perioperative medical management, 320
 PICC line placement, 311
 postoperative care, 313, 322, 329, 337
 premedication, 311
 preoperative evaluation, 308–9, 316–17, 318–20, 326–9, 334–5
 preoperative medication preparation, 311, 320, 321
 preoperative planning, 309
 ventilation strategy, 312–13, 328
 anesthetic risk, 6–7, 308–9, 316, 318–19
 assessment
 cardiac catheterization, 306–7, 308–9, 317, 318, 319, 324–5, 334
 echocardiography, 306–7, 309, 316–17, 324
 preoperative, 308–9, 316–17, 318–20
 severity, 318–19
 AVSDs with, 22, 27, 28–9
 classification, 306
 Panama, 333
 WHO, 306, 308, 333
 definition, 305
 diagnosis, 306–7
 diaphragmatic hernia with, 261
 Down syndrome and, 314, 315–16, 319–20
 medical therapy
 anticoagulation, 307, 334
 calcium channel blockers, 307, 320
 endothelin receptor antagonists, 307–8, 334
 goals, 307
 initial options, 307
 iNO, 11, 320, 321, 325
 mechanisms of action and potential side effects, 334
 perioperative management, 320
 phosphodiesterase inhibitors, 307–8, 320, 325, 334
 premature infants, 325
 preoperative considerations, 309
 prostacyclin, 320, 321
 prostacyclin analogs, 307–8, 334
 selection, 308
 moyamoya disease, 331
 anesthetic management, 334–7
 associated conditions, 331
 cerebral autoregulation, 332, 333
 coarctation of the aorta with, 332–3
 definition, 331
 diagnosis, 331–2
 treatment, 332
 PAH versus, 305
 pathophysiology, 305–6
 pentology of Cantrell, 65–6, 68
 prematurity, 323
 airway management, 325
 anesthetic implications, 326–9
 anesthetic risk, 327
 bronchopulmonary dysplasia and, 323–4, 325
 definition, 323
 diagnosis, 324–5
 iNO effects, 325
 medical management, 325
 risk factors, 324
 screening, 324
 shunt effects, 325–6
 sildenafil effects, 325
 pulmonary arterial hypertension, 28–9
 pulmonary hypertensive crisis, 310
 definition, 329
 presentation, 310, 321, 329
 treatment, 310–11, 321–2, 329
 PVR measurement, 5
 risk factors, 315
 bronchopulmonary dysplasia, 323–4
 Down syndrome, 314, 315–16
 Shone complex, 132
 trisomy 21 and risk for, 28–9
 VAD complications, 271
 pulmonary hypoperfusion, DORV with, 15–16, 17
 pulmonary insufficiency (PI), after TOF repair, 46, 47
 pulmonary overcirculation
 AVSDs, 20–3
 DORV, 15–16, 17
 truncus arteriosus, 180, 181
 ventilation and, 12
 VSDs, 11, 12
 pulmonary regurgitation (PR), peak velocity, 316–17
 pulmonary (pulmonic) stenosis (PS), 33.
 See also tetralogy of Fallot with pulmonary stenosis
 anesthetic implications
 balloon valvuloplasty evaluation, 38
 extubation, 37–8
 fluid administration, 37
 hemodynamic goals, 36–7
 induction plan, 37
 maintenance plan, 37
 postprocedural management, 38
 potential intraprocedural complications, 37
 preoperative cardiac evaluation and workup, 35–6
 surgical procedures for unsuccessful catheterization, 38
 ventilation strategy, 37
 associated lesions and syndromes, 34–5
 balloon valvuloplasty procedure, 35, 36
 critical, 33, 34–5
 definitions and classifications, 33
 DORV with, 15–16, 17–18
 subvalvular, 17
 supravalvular, 17
 valvular, 17
 oxygen saturation expectations, 35
 pathophysiology, 33, 34
 PGE₁ infusion, 35
 TGA with, 142, 143–4
 TOF with, 39–40, 41, 42
 tricuspid atresia with, 207–8
 pulmonary valve (PV). *See also* absent pulmonary valve syndrome; pulmonary (pulmonic) stenosis replacement of, after TOF repair, 47
 TOF with absent, 41, 52, 53
 pulmonary vascular occlusive disease (PVOD)
 AVSDs leading to, 20–2
 trisomy 21, 22, 28–9
 VSDs leading to, 10
 pulmonary vascular resistance (PVR)
 anesthetic effects, 12, 30, 31, 336
 AVSDs, 25–6, 30, 31
 BDG shunt, 204, 219
 cardiac catheterization data, 4, 5
 Ebstein anomaly, 75–6, 77, 81
 Fontan procedure patients, 221
 intraoperative reduction, 320
 pulmonary hypertension, 305, 314, 323–4, 325–6
 pulmonary hypertensive crisis, 310
 definition, 329
 presentation, 310, 321, 329
 treatment, 310–11, 321–2, 329
 pulmonic stenosis, 36–7
 shunts and, 3, 325–6
 TAPVR, 175, 176
 truncus arteriosus, 180, 181
 VAD considerations, 281
 VSDs, 9, 10–11, 12–13
 pulmonary veins. *See also* total anomalous pulmonary venous return stenosis, 323–4
 pulmonary venous obstruction (PVO), TAPVR, 169–70, 171, 174, 175–6
 pulmonary venous stenosis, recurrent, TAPVR and heterotaxy syndrome, 171
 PV. *See* pulmonary valve
 PVO. *See* pulmonary venous obstruction
 PVOD. *See* pulmonary vascular occlusive disease
 PVR. *See* pulmonary vascular resistance
 pyridostigmine, post–heart transplantation, 297
 Q_p. *See* pulmonary blood flow
 Q_p:Q_s ratio, 3
 balanced, 218
 calculation, 10–11
 cardiac catheterization data, 4, 5
 HLHS, 191
 anesthetic implications, 193–5
 stage I palliation, 191, 192
 TOF/PA/MAPCAs, 60, 62–3
 truncus arteriosus, 180, 181
 VSDs, 10–11
 Q_s. *See* systemic blood flow

- QT prolongation. *See also* long QT syndrome
 Williams syndrome, 106
- RA. *See* right atrium
 RAA. *See* right aortic arch
 RAS. *See* restrictive allograft syndrome
 Rastelli classification, 26
 Rastelli procedure, 141
 RCM. *See* restrictive cardiomyopathy
 rejection
 heart transplantation, 292
 lung transplantation, 284
 Remodulin®. *See* treprostinil
 renal dysfunction, Fontan failure, 229
 réparation à l'étage ventriculaire (REV), 141
 resistance. *See also* pulmonary vascular resistance; systemic vascular resistance
 cardiac catheterization data, 5
 restrictive allograft syndrome (RAS), 284–5
 restrictive ASD, 25–6
 restrictive cardiomyopathy (RCM), 252–3,
 254
 clinical presentation, 254
 incidence, 254
 intraoperative anesthetic goals, 257
 other cardiomyopathy phenotypes versus, 246–7
 pathophysiology, 254–5, 258
 prognosis and management options, 255
 restrictive ventricular septal defect, 10,
 25–6
 REV. *See* réparation à l'étage ventriculaire
 right aortic arch (RAA), 339, 340
 TOF, 41
 VACTERL association, 360, 362
 right atrial isomerism, 172
 right atrium (RA), TAPVR, 169–70
 right dominance, unbalanced AVSD, 28
 right ventricle (RV). *See also* Ebstein anomaly
 atrial switch procedure, 148–9, 150–2
 CCTGA, 160–1, 163–4
 congenital defects, 70, 71, 73, 75–6
 hypoplastic, tricuspid atresia with, 207–9
 LVAD use and, 277, 278
 pulmonary hypertension assessment, 317
 pulmonary hypertension effects, 325
 right ventricle to pulmonary artery (RV–PA) conduit, truncus arteriosus repair, 181
 stenosis, 182, 183–4
 right ventricular assist device (RVAD), 276, 278, 279
 decreased blood flow considerations, 281
 indications, 279
 respiratory support, 281–2
 right ventricular hypertrophy (RVH)
 TGA, 143
 TOF, 39–40
 right ventricular outflow tract (RVOT),
 stenting, 361, 365–6
 right ventricular outflow tract obstruction (RVOTO)
 DORV, 14–16
 dynamic, 40
 Ebstein anomaly, 75–6
 fixed, 40
 Tet spells and, 41
 after TGA repair, 141
 TOF, 3, 39–40, 43
 truncus arteriosus, 181, 183–4
 VACTERL association, 360–1
 right-to-left (R-to-L) shunting, Fontan failure, 229
 Ross classification for pediatric heart failure, 163, 164
 Ross procedure, valvular aortic stenosis, 93, 94
 surgical outcomes, 94–5
 Ross–Konno procedure
 subvalvular aortic stenosis, 101
 valvular aortic stenosis, 93–4, 95
 surgical outcomes, 94
 R-to-L shunting. *See* right-to-left shunting
 RV. *See* right ventricle
 RVAD. *See* right ventricular assist device
 RVH. *See* right ventricular hypertrophy
 RVOT. *See* right ventricular outflow tract obstruction
 RV–PA conduit. *See* right ventricle to pulmonary artery conduit
 SAM. *See* systolic anterior motion
 Sano shunt, stage I palliation, 189, 190,
 191, 192, 198–9
 saturation data, cardiac catheterization, 4
 SAV. *See* surgical aortic valvotomy
 SCD. *See* sudden cardiac death
 SCPA. *See* superior cavopulmonary anastomosis
 segmental approach, 2
 Senning procedure, 140, 146, 148
 CCTGA, 161–2
 Senning–Rastelli procedure, 162, 163
 series circulation, 3, 4, 137–8, 188, 226
 sevoflurane
 TOF patients, 43–4
 trisomy 21 patients, 29
 Shone complex, 129
 anesthetic implications
 afterload monitoring and management, 133–4
 anesthetic agent selection, 132
 contractility monitoring and management, 134
 intraoperative considerations, 133
 intravenous catheter placement, 132–3
 postoperative disposition, 134–5
 postoperative pain control, 134
 preload monitoring and management, 133
 preoperative evaluation, 132
 preoperative management, 132
 aortic coarctation correction, 131
 characteristic cardiac anomalies, 129–30, 131
 coarctation of the aorta, 121, 129, 130, 131
 correction surgery or techniques, 129–30, 131
 parachute mitral valve, 129, 130, 131
 partial, 129
 pulmonary hypertension, 132
 respiratory involvement, 132
 surgical approaches, 129–30, 131
 shortening fraction, 4, 6
 shunts, 2–3. *See also* specific shunts
 anatomic, 2, 3
 cardiac catheterization data, 4, 5
 complex, 3
 dependent (nonrestrictive), 3
 physiologic, 2, 3
 pulmonary hypertension with, 325–6
 simple, 3
 sildenafil, 325
 simple shunts, 3
 single ventricle palliation. *See also* Fontan procedure; stage I palliation; stage II palliation
 CCTGA, 162
 Ebstein anomaly, 72, 77, 78–9
 reason for staging, 198–9
 superior cavopulmonary anastomosis indications, 199
 single ventricle physiology, 187. *See also* hypoplastic left heart syndrome
 anesthetic risk, 6–7, 79
 cerebral perfusion pressure, 203–4
 parallel circulations, 3, 4
 TAPVR, 171, 173–4
 TGA with hypoplastic left ventricle, 217–18, 219–21
 tricuspid atresia, 207–9
 situs ambiguous, 2
 situs inversus, 2
 situs solitus, 2, 159–60
 stage I palliation, 198
 anesthetic implications
 anesthetic risk counselling, 192, 193
 ECMO capability considerations, 192, 196, 197
 extubation, 196–7
 failure to thrive, 192
 hypoxemia associated with hypertension, 195
 induction method and hemodynamic goals, 193–4
 intraoperative and postoperative analgesic options, 196
 laparoscopy considerations, 195–6
 open laparotomy considerations, 195–6

- stage I palliation (cont.)
 postoperative disposition, 196
 preoperative assessment, 192
 refractory hypoxemia, 196
 systemic and pulmonary blood flow management, 193–5
 systemic-to-pulmonary shunt considerations, 193–4
 vascular access and monitoring, 193
 ventilation strategy, 194
 blood flow pattern after, 190
 hybrid approach, 190, 191
 repair timing, 188
 surgical procedure and goals, 189–90
 surgical stages after, 191
- stage II palliation, 191, 198. *See also* bidirectional Glenn shunt
 BDG shunt procedure, 198, 199, 200
 blood flow pattern after, 199–201
 hemi-Fontan procedure, 191, 198, 199, 200
 indications for SCPA, 199
 oxygen saturation expectations, 201
 physiologic goals, 199
 reason for staging, 198–9
 tricuspid atresia, 208–9
- Starnes procedure, 72, 77, 78–9
- sternal malformations, pentalogy of Cantrell, 65, 67–8
- stress dose steroids, 296
- stress perfusion CMRI, 354–5
- subaortic stenosis
 AVSDs, 22, 23
 DORV, 14–15
 Shone complex, 129, 130
- subaortic ventricular septal defect, 15–16, 17
- subarterial/subpulmonic ventricular septal defect, 9, 10, 15–16
- subclavian artery, aberrant origin of, TOF, 41
- subvalvular aortic stenosis. *See* aortic stenosis
- succinylcholine
 Duchenne muscular dystrophy, 242, 244
 long QT syndrome, 378–9
- sudden cardiac death (SCD)
 HCM, 113
 long QT syndrome, 374, 375, 376
 after TOF repair, 46–7
 Williams syndrome, 107
 risk factors, 107, 111
- suicide right ventricle, 38
- superior cavopulmonary anastomosis (SCPA), 28, 173. *See also* bidirectional Glenn shunt
- central venous access considerations, 203
 indications, 199
 stage II palliation, 191, 198, 199, 200
 BDG versus hemi-Fontan, 199, 200
 cerebral perfusion pressure effects, 203–4
 for tricuspid atresia, 208–9
- TGA with hypoplastic left ventricle, 219
- supravalvular aortic stenosis (SVAS), 90, 91, 105. *See also* Williams syndrome
 surgical repair indications, 107
 without WS, 106
- supravalvular pulmonary artery stenosis (SVPS), Williams syndrome, 105–6
- supraventricular reentrant tachycardia, 147
- surgical aortic valvotomy (SAV), aortic stenosis, 84, 85, 86, 93
- SVAS. *See* supravalvular aortic stenosis
- SVPS. *See* supravalvular pulmonary artery stenosis
- SVR. *See* systemic vascular resistance
- syncope, HCM, 114
- systemic blood flow (Q_s). *See also* $Q_p:Q_s$ ratio
 cardiac catheterization data, 4, 5
 effective, 2
 total, 3
- systemic circulation, series versus parallel, 3, 4
- systemic vascular resistance (SVR)
 anesthesia effects, 12, 30, 31
 AVSDs, 25–6, 30, 31
 cardiac catheterization data, 4, 5
 pulmonary hypertensive crisis treatment, 310–11
 Shone complex, 133–4
 shunts and, 3
 truncus arteriosus, 180, 181
 VAD considerations, 274
 VSDs, 10–11, 12
- systemic-to-pulmonary artery shunt. *See also* modified Blalock-Taussig shunt
 TAPVR and heterotaxy syndrome, 173–4
 TOF, 42
- systolic anterior motion (SAM), mitral valve, 114
- TA. *See* tricuspid atresia; truncus arteriosus
- tachycardia
 cardiomyopathy, 115, 250, 257
 post-heart transplantation, 294
 Shone complex, 134
- tacrolimus, 296–7
- TAPSE. *See* tricuspid annular plane systolic excursion
- TAPVR. *See* total anomalous pulmonary venous return
- Taussig-Bing anomaly, 15–16
- TCPA. *See* total cavopulmonary anastomosis
- TEF. *See* tracheoesophageal fistula
- tet spells, 41, 52, 360. *See also* tetralogy of Fallot
 management, 43–4, 361
 pink tets, 42, 360–1
 preoperative assessment, 43
 variability in, 2
- tetralogy of Fallot (TOF)
 absent pulmonary valve and, 41, 52, 53
 anatomy, 39–40, 45, 360
 associated cardiac lesions, 41
 associated genetic syndromes, 47–8
 diagnosis, 360
 DiGeorge syndrome, 48
 genetic testing in, 47–8
 MAPCAs and, 41, 57, 58, 60
 obstruction and shunting, 3
 pathophysiologic and anatomic variations, 2, 41, 46
 pulmonary atresia and, 41, 57, 58
 pulmonic stenosis and, 39–40, 41, 42
 surgical approaches, 45–6
 postoperative sequelae, 46, 47
 VACTERL association, 360–1, 362, 365–6
- tetralogy of Fallot (TOF), repaired, 45
 anesthetic implications
 anesthetic risks, 49
 bacterial endocarditis prophylaxis, 49
 extubation, 51
 induction options, 50
 intraoperative arrhythmias, 50–1
 intraoperative fluid management, 50
 intraoperative monitoring, 50
 maintenance goals, 50
 peripheral intravenous catheter placement, 49–50
 postoperative monitoring, 51
 premedication, 49
 preoperative assessment, 48–9
 preoperative testing, 49
 cardiac anomalies of TOF, 45
 chronic postoperative sequelae, 46, 47
 DiGeorge syndrome relevance, 48
 extracardiac manifestations of genetic syndromes associated with TOF, 48
 genetic testing, 47–8
 ICD placement consideration, 46–7
 pulmonary valve replacement consideration, 47
 TOF variation impacts on repair, 46
 transannular patch implications, 46
 typical surgical approaches, 45–6
 ventriculotomy implications, 46
- tetralogy of Fallot with absent pulmonary valve syndrome (TOF/APVS), 52
 anatomic features, 52, 53
 anesthetic implications
 induction options, 55
 lower airway obstruction, 55
 postoperative issues, 56
 preoperative evaluation, 54–5
 ventilation strategies, 53–4, 55–6
- chest imaging findings, 54
- PDA role, 53
- respiratory pathology, 41, 52, 53–4
- surgical repair options and
 considerations, 54
 symptomatology, 53–4

- tetralogy of Fallot with pulmonary atresia and multiple aortopulmonary collaterals (TOF/PA/MAPCAs), 57
anatomic characteristics, 57, 58
anesthetic implications
associated genetic syndromes, 61
imaging, 61–2
induction and maintenance
considerations, 62–3
postoperative disposition, 63
preoperative assessment priorities, 62
blood flow path at birth, 58
long-term complications, 60–1
MAPCA impacts, 58, 60
oxygen saturation, Q_p/Q_s ratio, and hemodynamics, 60, 62–3
pulmonary blood flow, 57, 58, 60
surgical palliative or repair approaches, 58–60
- tetralogy of Fallot with pulmonary stenosis (TOF/PS), 39**
- anatomic variations, 41
anesthetic implications
induction options, 43
maintenance considerations, 44
peripheral intravenous line placement, 43
physical examination findings, 43
postoperative care, 44
preoperative assessment questions, 43
preoperative diagnostic tests, 42–3
tet spell management, 43–4
associated lesions or abnormalities, 41
defects present in classic TOF, 39–40
overriding aorta, 39–40
pink tet, 42
repair timing and procedures, 42
RVOTO, 39–40
tet spell severity, 41
VSD, 39–40
- TGA. See transposition of the great arteries
- TGA-IVS. See transposition of the great arteries with intact ventricular septum
- TGA-type DORV, 15–16, 17
- TGA-VSD. See transposition of the great arteries with ventricular septal defect
- thromboembolism, Fontan failure, 230
- Timothy syndrome, 376. *See also* long QT syndrome
- TOF. *See* tetralogy of Fallot
- TOF/APVS. *See* tetralogy of Fallot with absent pulmonary valve syndrome
- TOF/PA/MAPCAs. *See* tetralogy of Fallot with pulmonary atresia and multiple aortopulmonary collaterals
- TOF/PS. *See* tetralogy of Fallot with pulmonary stenosis
- TOF-type DORV, 15–16, 17
- torsades de pointes, 374
- management, 379
total anomalous pulmonary venous return (TAPVR), 169
anatomic characteristics, 169–70
anatomic subtypes and classification
cardiac, 170, 171
infracardiac, 170, 171
mixed, 170, 171
supracardiac, 170, 171
anesthetic implications
extubation, 176
induction and maintenance methods, 174–5
intraoperative concerns, 175–6
malrotation management, 173
monitoring, 174
postoperative management, 176
preoperative evaluation, 174
risk discussion, 173–4
ventilation strategy, 175
anesthetic risk, 173–4
associated cardiac defects, 171
heterotaxy syndrome with, 169–70, 171
classification, 172
infection-related precautions, 173
organ involvement, 172
perioperative outcomes, 171
incidence, 169
postoperative sequelae, 171
pulmonary venous obstruction with, 169–70, 171, 174, 175–6
surgical repair, 171
- Total Artificial Heart, 268
- total blood flow, 3
- total cavopulmonary anastomosis (TCPA), 219, 227–8. *See also* Fontan procedure
- TPG. *See* transpulmonary gradient
- TR. *See* tricuspid regurgitation
- tracheobronchomalacia, APVS, 41, 53–4, 55–6
- tracheoesophageal fistula (TEF), 359–60, 361. *See also* esophageal atresia
- tranexamic acid, 127
- transannular patch, TOF repair, 45–6
- transfusion
Fontan procedure patients, 214–15
guidelines, 127
- transitional atrioventricular septal defect, 20–2
- transposition of the great arteries (TGA), 137, 145. *See also* arterial switch operation; atrial switch procedure; congenitally corrected transposition of the great arteries
anatomy, 137, 138, 145
anesthetic implications
anesthetic risk counselling, 142–3
cardiac catheterization procedures, 152–3
general anesthetic considerations for pulmonary stenosis, 143
- high-risk patients, 151–2
induction considerations, 143–4
monitoring and invasive access
considerations, 143, 152, 153
outpatient considerations, 144
preoperative assessment, 142, 150–1
procedure location, 144, 156
pulmonary stenosis diagnosis, 142
ventilation strategy, 144
anesthetic risks, 142–3, 151–2
associated anomalies, 139
atrioventricular discordance, 158, 159
dextro-, 137–8, 145
subtypes, 138–9
DORV and, 14–15
historical background, 146
levo-, 137–8, 146, 158–9
newborn physiology, 138–9
parallel circulations in, 3, 4, 137–8
physiologic shunting in, 2
series circulation in, 137–8
surgical approaches, 140
arterial switch operation, 17, 140, 141, 145
atrial switch procedure, 140, 145, 146, 147, 148–50
follow-up, 142, 149–50
long-term complications, 141, 147, 148, 149, 150
Mustard procedure, 140, 146, 147
Nikaidoh procedure, 141
Rastelli procedure, 141
REV, 141
Senning procedure, 140, 146, 148
ventriculoarterial discordance, 137–8, 158, 159, 217
- transposition of the great arteries with intact ventricular septum (TGA-IVS), 138, 139, 141
- transposition of the great arteries with left ventricular outflow tract obstruction (TGA-LVOTO), 138, 139, 140–1
- transposition of the great arteries with ventricular septal defect (TGA-VSD), 138, 139, 141
- transpulmonary gradient (TPG), 209–10, 219, 223, 226
- treprostинil (Remodulin[®]), 320
- tricuspid annular plane systolic excursion (TAPSE), 149
- tricuspid atresia (TA), 207
anatomy, 207–8
blood flow pathway, 208
classifications, 208
pulmonary blood flow sources, 208
surgical approaches, 208–9
Fontan procedure, 209
- tricuspid regurgitation (TR)
atrial switch procedure, 148–9, 150–2
- CCTGA, 160–1, 163

tricuspid regurgitation (TR) (cont.)
 Ebstein anomaly, 70, 71, 72, 74, 75–6,
 77–8
 pulmonary hypertension, 306–7, 316
 tricuspid valve (TV). *See also* Ebstein
 anomaly
 CCTGA abnormalities, 161
 congenital defects, 70, 71, 75–6
 triple therapy, pulmonary arterial
 hypertension, 308
 trisomy 13, 14–15
 trisomy 18, 14–15
 trisomy 21. *See* Down syndrome
 truncus arteriosus (TA), 178
 anatomic characteristics, 178, 179
 anesthetic implications
 anomalies associated with 22q11DS,
 181, 182
 endocarditis prophylaxis, 183
 intraoperative anesthetic plan, 183–4
 postoperative care, 184
 preoperative evaluation, 182
 RV-PA conduit stenosis
 management, 183–4
 associated anomalies, 179–80
 classifications
 Collett and Edwards, 178–9
 modified Van Praagh, 178–9
 coronary blood flow and myocardial
 perfusion, 180, 181
 incidence, 178, 179–80
 natural history, 180, 181
 oxygen saturation, 180
 pulmonary and systemic blood flow
 distribution, 180
 surgical repair, 181
 postoperative complications and
 long-term sequelae, 181
 tunnel-type subvalvular aortic stenosis, 98,
 99
 Turner syndrome, coarctation of the aorta,
 121
 TV. *See* tricuspid valve
 22q11.2 microdeletion syndrome
 (22q11DS), 14–15. *See also*
 DiGeorge syndrome
 anomalies associated with, 181, 182
 TOF with, 41, 47–8
 TOF/PA/MAPCAs with, 61
 truncus arteriosus with, 179–80, 181, 182
 two-ventricle repair, Ebstein anomaly, 72, 77
 unbalanced common atrioventricular
 septal defect, 25
 anatomic characteristics of complete
 AVSD, 25, 26
 anesthetic implications
 arterial and central line monitoring, 29
 intraoperative hypotension
 considerations, 30, 31
 laparoscopic surgery considerations,
 29–30

medications for anesthesia induction
 and maintenance, 30
 patients with trisomy 21, 28–9
 postoperative considerations, 31
 preoperative diagnostic tests, 29
 pulmonary hypertension risk, 28–9
 ventilation management, 30
 cardiac surgical treatment options, 28
 degree of unbalance in, 28
 implications, 27
 long-term survival expectations, 28
 L-to-R shunting, 25–6
 neonatal symptoms of complete AVSD,
 27
 physiologic issues of complete AVSD, 25
 Rastelli classification, 26
 right dominance versus left dominance,
 28
 trisomy 21 relationship, 27
 ventricular dominance, 28
 unifocalization, aortopulmonary
 collaterals, 58–60
 VACTERL association, 48, 359
 anesthetic implications
 airway and ventilation management,
 362–3, 364
 cardiorespiratory compromise, 364
 complications, 365
 extubation, 365
 hypoxemia management, 365–6
 induction and intubation technique,
 363
 monitoring, 364
 open TEF repair, 364–5
 postoperative care, 365
 preoperative bronchoscopy, 363
 preoperative workup, 362
 thoracoscopic TEF repair, 364
 cardiac anomalies, 359
 definition, 359
 esophageal atresia/tracheoesophageal
 fistula, 359–60, 361
 TOF, 360–1, 362, 365–6
 VAD. *See* ventricular assist device
 valvular aortic stenosis. *See* aortic stenosis
 valvulopathies. *See also* specific valves
 hemodynamic goals, 371
 vascular rings, 338
 anesthetic implications
 airway management, 342–3
 emergence and extubation plan, 343
 induction method, 342–3
 management goals, 342
 monitoring, 342–3
 multiple procedures, 341–2
 postoperative care, 343
 preoperative evaluation, 341
 respiratory infection considerations,
 341
 associated lesions, 340
 clinical presentation, 339–40
 definition and anatomy, 338
 diagnosis, 340
 embryopathogenesis, 339
 incidence, 338–9
 outcomes, 343
 surgical repair, 340
 monitoring, 342–3
 types, 339
 vasopressin, HCM, 119
 veno-arterial ECMO, 263, 264, 266–7
 veno-venous ECMO, 263, 264, 266–7,
 281–2
 ventilation strategy
 AVSD, 30
 BDG shunt, 204–5
 diaphragmatic hernia, 262
 Ebstein anomaly, 73–4, 81
 ECMO, 264–5
 Fontan procedure patients, 212, 224, 234
 HCM, 120
 lung transplantation, 288
 pentology of Cantrell, 68
 pulmonary hypertension, 312–13, 328
 pulmonary overcirculation and, 12
 pulmonary stenosis, 37
 stage I palliation, 194
 TAPVR, 175
 TGA, 144
 TOF/APVS, 53–4, 55–6
 VACTERL association, 362–3, 364
 ventricular assist device (VAD)
 anesthetic implications, 273
 anticoagulation, 271–2, 274, 279, 280
 complications, 271, 273
 decreased blood flow considerations,
 281
 device management, 273–4
 expected surgical procedures, 272
 hematologic considerations, 274, 280
 hemodynamic considerations, 274, 281
 infection control, 274
 invasive line placement, 274
 management plan, 272, 280
 patient transport, 279–80
 preanesthesia assessment, 272
 respiratory support, 281–2
 biventricular, 279
 classifications
 axial pump, 268, 277
 centrifugal pump, 268, 277
 continuous flow pumps, 268, 277
 extracorporeal, 277
 intracorporeal, 277
 long-term, 277
 paracorporeal pump, 268
 pulsatile pumps, 268, 277
 short-term, 277
 components, 268
 definition, 268
 devices
 Berlin Heart EXCOR, 268–9, 270–2,
 273–4, 275, 277

- CentriMag, 268, 278, 279
 HeartMate 3, 268
 HeartMate II, 268, 277
 HeartWare, 268, 277, 278
 Total Artificial Heart, 268
 ECMO versus, 264, 276
 indications, 270–1
 left, 268, 271
 Berlin Heart EXCOR, 268–9, 270
 right ventricular failure, 278, 279
 right ventricular function, 277
 loss of device output, 273
 outcomes, 271
 pediatric design challenges, 270
 right, 276, 278, 279
 decreased blood flow considerations, 281
 indications, 279
 respiratory support, 281–2
 selection, 268
 ventricular dysfunction
 anesthetic risk, 6–7, 79
 Fontan failure, 229
 ventricular inversion, 159, 160. *See also*
 congenitally corrected
 transposition of the great arteries
 ventricular septal defect (VSD), 9
 anesthetic implications
 anesthetic plan, 13
 diuretic therapy issues, 12
 postoperative monitoring, 13
 preoperative considerations, 11–12
 PVR and SVR effects, 12
 CCTGA, 161, 163
 characterization, 9, 10
 complete AVSD with, 25, 26
 degree of shunting, 11
 DORV compared with, 14
 doubly committed, 15–16
 great artery relationships to, 14, 15, 16
 hemodynamic effects, 9
 inlet, 9, 10, 25, 26
 malalignment, 40
 muscular, 9, 10
 noncommitted, 15–16
 nonrestrictive, 10, 25–6
 parallel circulations, 4
 perimembranous, 9
 pulmonary atresia/MAPCAs and, 58, 59
 pulmonary overcirculation, 11, 12
 pulmonary stenosis with, 15–16, 17–18
 Q_p/Q_s ratio, 10–11
 repair age and considerations, 11
 restrictive, 10, 25–6
 restrictive compared with
 nonrestrictive, 10
 subaortic, 15–16, 17
 subarterial/subpulmonic, 9, 10, 15–16
 TGA with, 138, 139, 141
 TOF with, 3, 39–40
 tricuspid atresia with, 207–8
 ventricular tachycardia, after TOF repair, 46–7, 50–1
 ventriculoarterial alignment, DORV
 concordant, 15–16
 discordant, 15–16
 ventriculoarterial discordance, 137–8, 158, 159, 217
 ventriculotomy, TOF repair, 46
 visceral situs, 2
 volatile agents
 long QT syndrome, 378
 pulmonary hypertension effects, 312
 PVR and cerebral perfusion effects, 336
 VSD. *See* ventricular septal defect
 VSD-type DORV, 15–16, 17
 WHO. *See* World Health Organization
 Williams syndrome (WS), 34–5, 105
 anesthetic considerations, 107–11
 anesthetic risk, 6–7, 107, 111
 cardiac abnormalities, 105–6
 cardiac arrest, 107
 cardiac surgical repair indications, 107
 coronary artery abnormalities, 105–6, 107, 108, 111
 elastin deficiency in, 105
 hemodynamic management, 109
 physical characteristics, 107–8
 QT prolongation, 106
 Williams–Beuren syndrome. *See* Williams syndrome
 Wolff–Parkinson–White syndrome (WPW), 71, 74, 160–1
 Wood units (WU), 305
 World Health Organization (WHO),
 pulmonary hypertension classification, 306, 308, 333
 WPW. *See* Wolff–Parkinson–White syndrome
 WS. *See* Williams syndrome
 WU. *See* Wood units
 z-score, 6, 387

